Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.
Last trade$159.55
Day change+$2.45 (+1.56%)
Day range$154.05 – $162.68
Volume628,880
Market cap$6.23B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.23B
Price / earnings
6.11×
Price / book
1.78×
Price / sales
3.69×
EV / sales
4.41×
EV / EBITDA
22.06×
Profitability
Earnings per share
$25.69
Return on assets
16.05%
Return on equity
29.17%
Dividend yield
0.94%
Liquidity and leverage
Debt / equity
0.47×
Current ratio
2.28×
Quick ratio
1.81×
Cash ratio
0.53×
Cash flow
Price / cash flow
14.05×
Price / free cash flow
16.05×
Free cash flow
$388.23M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TFX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 28, 2025
Q2 FY2025 Jun 29, 2025
Q1 FY2025 Mar 30, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$567.78M
$570.33M
$548.26M
—
$566.95M
$442.53M
$414.26M
$795.41M
Cost of revenue
$199M
$238.63M
$240.84M
$0
$274.9M
$176.7M
$158.83M
$355.49M
Gross profit
$368.79M
$331.71M
$307.43M
—
$292.05M
$265.83M
$255.43M
$439.92M
Selling, general and administrative
$220.72M
$213.52M
$226.01M
—
$207.38M
$137.5M
$152.91M
$254.55M
Research and development
$42.98M
$45.12M
$44.39M
—
$44.26M
$26.49M
$25.3M
$44.55M
Total operating expenses
$263.36M
$258.88M
$287.24M
—
$354.48M
$174.69M
$179.63M
$550.3M
Operating income
$105.43M
$72.82M
$20.18M
—
-$62.44M
$91.14M
$75.8M
-$110.38M
Interest expense
-$21.21M
-$27.95M
-$25.72M
—
-$31.83M
-$21.7M
-$18.54M
-$18.64M
Income before taxes
$83.12M
$45.14M
-$3.83M
—
-$92.44M
$70.66M
$58.75M
-$126.76M
Income taxes
$246.17M
$3.38M
$1.01M
—
-$29.7M
$2.49M
$6.42M
$9.9M
Net income
$927.43M
$102.02M
-$8.15M
—
-$408.89M
$132.75M
$95M
-$136.66M
Net income attributable to common shareholders
$927.43M
$99.69M
-$8.15M
—
-$408.89M
$122.58M
$95M
-$136.66M
EBITDA
$156.66M
$122.89M
$90.77M
-$33.23M
$89.06M
$138.73M
$115.84M
$99.53M
Basic earnings per share
$22.36
$2.29
-$0.18
—
-$9.24
$2.77
$2.08
-$2.94
Diluted earnings per share
$22.28
$2.28
-$0.18
—
-$9.24
$2.77
$2.07
-$2.93
Recent news
Company coverage with links to the original publishers.
Steris reported quarterly earnings of $2.94 per share, beating consensus estimates of $2.67 and surpassing year-ago earnings of $2.47. The company also exceeded revenue expectations with $1.59 billion versus consensus of $1.56 billion. Despite strong earnings performance, Steris shares have underperformed the S&P 500 by 19.3% year-to-date. The stock holds a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.
ResearchAndMarkets.com released a comprehensive market report on China's airway management sector, covering historical data from 2018 and forecasts through 2033. The report segments the market into Airway Management Tubes and Intubation Accessories, providing revenue, volume, and pricing analysis. It includes 2025 company share data and profiles of key competitors to support strategic planning and investment decisions in this growing medical device market.
Bruker Corporation (BRKR) shares gained 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry. However, the company faces a $134.9M goodwill impairment, currency headwinds, and restructuring costs. Full-year 2026 revenue guidance was lowered to $3.54-$3.57B due to currency pressures, though the company maintains a solid financial position with $184.9M in cash.
Globus Medical (GMED) reported strong Q2 2026 performance with musculoskeletal revenues rising 7.5% and base business sales up 10.9%. The company continues to gain market share through product innovation, with over 60 development projects underway. However, foreign exchange volatility remains a concern. GMED maintains a debt-free balance sheet with $507.7 million in cash, supporting continued R&D and expansion investments.
Charles River Laboratories (CRL) has outperformed the market with a 75.8% share price increase over the past year, driven by strong Research Models and Services (RMS) prospects and adoption of new approach methodologies. However, the company faces headwinds from uneven demand recovery across client segments, with small and midsized biotech revenues flat and currency fluctuations impacting reported growth. The company maintains a Zacks Rank #3 (Hold) rating.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Nov 16, 2026
$0.34
Dec 31, 2026
recurring
Aug 14, 2026
$0.34
Sep 30, 2026
recurring
May 22, 2026
$0.34
Jun 30, 2026
recurring
Mar 6, 2026
$0.34
Mar 31, 2026
recurring
Nov 14, 2025
$0.34
Dec 15, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.